Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.
Recon speaks with AJMC on emerging outcomes data for high touch primary care models in commercial populations
By
Jacob Wiesenthal and Tory Wolff
In the News
Read more
AJMC: More frequent visits to primary care can save net $30-40 PMPM for top 20% highest risk commercial members
By
Jacob Wiesenthal and Tory Wolff
Payers
,
Providers
Read more
Recon analysis in AJMC demonstrates, for the first time for commercially covered patients, the value of risk-stratifying primary care visit frequency
By
Jacob Wiesenthal and Tory Wolff
In the News
Read more
Are some of Kaiser’s regional ambitions starting to pay off?
By
Jacob Wiesenthal and Tory Wolff
Payers
,
Providers
Read more
The coming site-of-care shock for infusions
By
Jacob Wiesenthal and Tory Wolff
Biopharma
,
Payers
,
Providers
Read more
The ongoing physician affiliation land grab in Pennsylvania’s Capital District
By
Jacob Wiesenthal and Tory Wolff
Providers
Read more
Profit engine swap-outs: How UPMC sustained itself after the Highmark decoupling
